Lupin Launches Leflunomide Tablets USP

Pharma major Lupin Limited (Lupin) announced the launch of Leflunomide Tablets USP, 10 mg and 20 mg, having received an approval from the United States Food and Drug Administration (U.S. FDA) earlier. The product would be manufactured at Lupin's Pithampur (Unit I) facility in India.

Leflunomide Tablets USP, 10 mg and 20 mg, is the generic equivalent of Arava® Tablets, 10 mg and 20 mg, of Sanofi-Aventis U.S. LLC., and is indicated for the treatment of adults with active rheumatoid arthritis (RA).

Leflunomide Tablets USP (RLD: Arava®) had an annual sales of approximately USD 42 million in the U.S. (IQVIA MAT June 2020).

Shares of LUPIN LTD. was last trading in BSE at Rs.952 as compared to the previous close of Rs. 927.55. The total number of shares traded during the day was 94096 in over 3468 trades.

The stock hit an intraday high of Rs. 954.95 and intraday low of 918.95. The net turnover during the day was Rs. 88056817.

Source : Equity Bulls

Keywords